Company intelligence / Profile preview

cellNUA

Ownership: Private
Development stage: Other

Overview

cellNUA has developed the BEEMAR™ platform—a synthetic-free immunotherapy that has shown high efficacy in laboratory and preclinical models against a range of viruses and parasites. The company reports up to “99.99% efficacy” in lab settings versus major viral families and promising preclinical results against Plasmodium (malaria). Clinical trials are planned for malaria in Ghana starting Q1/Q3 next year. No published human trial data yet.

Therapeutic areas: Infectious Diseases
Modalities: Cell-based therapiesNatural immunotherapeutics (synthetic-free)
Industry: Biotech

Drug pipeline

1 asset

OcuNASE

Preclinical

Partnerships

Noguchi Memorial Institute for Medical Research in Ghana—collaborating on preclinical/clinical work on malaria therapy.

Beyond the preview

Go deeper on cellNUA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cellNUA.